These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 29628274)

  • 21. Oncostatin M is a potential agent for the treatment of obesity and related metabolic disorders: a study in mice.
    Komori T; Tanaka M; Furuta H; Akamizu T; Miyajima A; Morikawa Y
    Diabetologia; 2015 Aug; 58(8):1868-76. PubMed ID: 25972231
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunomodulatory liposomes targeting liver macrophages arrest progression of nonalcoholic steatohepatitis.
    Maradana MR; Yekollu SK; Zeng B; Ellis J; Clouston A; Miller G; Talekar M; Bhuyan ZA; Mahadevaiah S; Powell EE; Irvine KM; Thomas R; O'Sullivan BJ
    Metabolism; 2018 Jan; 78():80-94. PubMed ID: 28941597
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nano- and micro-based inhaled drug delivery systems for targeting alveolar macrophages.
    Lee WH; Loo CY; Traini D; Young PM
    Expert Opin Drug Deliv; 2015 Jun; 12(6):1009-26. PubMed ID: 25912721
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Macrophage MicroRNAs as Therapeutic Targets for Atherosclerosis, Metabolic Syndrome, and Cancer.
    Wei Y; Zhu M; Schober A
    Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29899293
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interactions with the macrophages: An emerging targeted approach using novel drug delivery systems in respiratory diseases.
    Mehta M; Deeksha ; Sharma N; Vyas M; Khurana N; Maurya PK; Singh H; Andreoli de Jesus TP; Dureja H; Chellappan DK; Gupta G; Wadhwa R; Collet T; Hansbro PM; Dua K; Satija S
    Chem Biol Interact; 2019 May; 304():10-19. PubMed ID: 30849336
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recent advances in endocrine metabolic immune disorders drug targeting: an editorial overview.
    Magrone T; Jirillo E
    Endocr Metab Immune Disord Drug Targets; 2015; 15(1):1-8. PubMed ID: 25800124
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Passive lung-targeted drug delivery systems via intravenous administration.
    Wei Y; Zhao L
    Pharm Dev Technol; 2014 Mar; 19(2):129-36. PubMed ID: 23336716
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Liposomal drug delivery systems: from concept to clinical applications.
    Allen TM; Cullis PR
    Adv Drug Deliv Rev; 2013 Jan; 65(1):36-48. PubMed ID: 23036225
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Macrophage-targeted delivery systems for nucleic acid therapy of inflammatory diseases.
    Singh A; Talekar M; Raikar A; Amiji M
    J Control Release; 2014 Sep; 190():515-30. PubMed ID: 24747762
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune Cells and Metabolism.
    Chatzigeorgiou A; Chavakis T
    Handb Exp Pharmacol; 2016; 233():221-49. PubMed ID: 25903417
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Macrophage reprogramming for therapy.
    Bart VMT; Pickering RJ; Taylor PR; Ipseiz N
    Immunology; 2021 Jun; 163(2):128-144. PubMed ID: 33368269
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The transcriptional coregulator GRIP1 controls macrophage polarization and metabolic homeostasis.
    Coppo M; Chinenov Y; Sacta MA; Rogatsky I
    Nat Commun; 2016 Jul; 7():12254. PubMed ID: 27464507
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeted delivery of curcumin for treating type 2 diabetes.
    Maradana MR; Thomas R; O'Sullivan BJ
    Mol Nutr Food Res; 2013 Sep; 57(9):1550-6. PubMed ID: 23495213
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multi-Target Drugs Against Metabolic Disorders.
    Scotti L; Scotti MT
    Endocr Metab Immune Disord Drug Targets; 2019; 19(4):389-390. PubMed ID: 31274061
    [No Abstract]   [Full Text] [Related]  

  • 35. Chronic Trypanosoma cruzi infection potentiates adipose tissue macrophage polarization toward an anti-inflammatory M2 phenotype and contributes to diabetes progression in a diet-induced obesity model.
    Cabalén ME; Cabral MF; Sanmarco LM; Andrada MC; Onofrio LI; Ponce NE; Aoki MP; Gea S; Cano RC
    Oncotarget; 2016 Mar; 7(12):13400-15. PubMed ID: 26921251
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting bile-acid signalling for metabolic diseases.
    Thomas C; Pellicciari R; Pruzanski M; Auwerx J; Schoonjans K
    Nat Rev Drug Discov; 2008 Aug; 7(8):678-93. PubMed ID: 18670431
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Therapeutic targeting strategies using endogenous cells and proteins.
    Parayath NN; Amiji MM
    J Control Release; 2017 Jul; 258():81-94. PubMed ID: 28483514
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Heart targeted nanoliposomal/nanoparticles drug delivery: An updated review.
    Cheraghi M; Negahdari B; Daraee H; Eatemadi A
    Biomed Pharmacother; 2017 Feb; 86():316-323. PubMed ID: 28011379
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immune regulation of metabolic homeostasis in health and disease.
    Brestoff JR; Artis D
    Cell; 2015 Mar; 161(1):146-160. PubMed ID: 25815992
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Selective delivery of drugs encapsulated in liposomes: natural targeting to macrophages involved in various disease states.
    Schroit AJ; Hart IR; Madsen J; Fidler IJ
    J Biol Response Mod; 1983; 2(2):97-100. PubMed ID: 6644336
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.